Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non–Small-Cell Lung Cancer

摘要: Remarkable developments in the systemic treatment of advanced non–small-cell lung cancer have taken place past few years. Targeted therapies been largely employed patients with far disease, and some them demonstrated consistent activity this setting. Epidermal growth factor receptor (EGFR) inhibitors cause dramatic response approximately 10% white who had received prior chemotherapy. Responses are higher Asians. These findings at least partly caused by substantially incidence EGFR mutations Asians compared whites. Studies combination chemotherapy front-line therapy have, however, failed to improve survival, better understanding interactions between chemotherapeutic agents will be essential development more effective strategies.